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Abstract 
A clinical diagnosis of Alzheimer’s disease can currently be made on the basis of results from cognitive 
tests in combination with medical history and general clinical evaluation, but the peptide amyloid-beta 
(Aβ) in cerebrospinal fluid (CSF) is increasingly used as a biomarker for amyloid pathology in clinical 
trials and in recently proposed revised clinical criteria for AD. Recent analytical developments have 
resulted in mass spectrometry (MS) reference measurement procedures for absolute quantification of Aβ1-
42 in CSF. Our aim was to cross-validate the Aβ1-42 concentrations, the Aβ1-42/Aβ1-40 and the Aβ1-42/Aβ1-38 
ratios in CSF measured by MS by comparing with plaque load as measured by amyloid positron emission 
tomography (PET). Validation results of the MS method showed that the method was linear (R2 >0.99) 
throughout the measurement range for all calibrator curves with relative errors below 15%. Repeatability 
and the intermediate precision were below 10% and 15 % respectively. Samples can go through up to five 
freeze/thaw cycles and be stored in -20° C with no significant effect on the measured concentration of the 
analyte. We included 100 non-demented patients with cognitive symptoms from the Swedish BioFINDER 
study, all of whom had undergone both lumbar puncture and 18F-flutemetamol PET. When using the CSF 
Aβ1-42 concentration for comparison with 18F-flutemetamol PET, 66% of all patients were classified 
identically with an area under the receiver operating characteristic (ROC) curve of 0.85 (95% CI, 0.78-
0.93) and a sensitivity and specificity of 82% and 81% respectively. Using the ratio of Aβ1-42/Aβ1-40 
significantly improved the concordance, classifying 89% of the patients identically, with an area under the 
ROC curve of 0.95 (95% CI, 0.90-1.00) and a sensitivity and specificity of 96% and 91% respectively. 
Similar results were obtained when using the Aβ1-42/Aβ1-38 ratio. 
These results show that the CSF Aβ1-42/Aβ1-40 ratio using the described MS method is strongly associated 
with the amount of cortical Aβ deposition measured by 18F-flutemetamol PET.  
 
Introduction 
Alzheimer’s disease (AD) affects about 35 million people worldwide, making it the most common form of 
dementia[1]. Neuropathologically, the disease is characterized by intracellular neurofibrillary tangles of 
accumulated hyperphosphorylated tau protein[2], and extracellular plaques consisting of aggregated 
amyloid-β (Aβ) peptides, which are widely believed to lie at the core of AD pathogenesis[3, 4]. In line 
with this, the plaque pathology in vivo, assessed by biomarkers, has recently been included in the research 
criteria for AD[5]. 
 
There are currently two established methods to identify Aβ accumulation in the brain in vivo: by positron 
emission tomography (PET) imaging of the brain using different Aβ-binding tracers and by measuring the 
concentration of Aβ1-42 in the cerebrospinal fluid (CSF). Several amyloid tracers are available to assess the 
amount of deposited Aβ in the cortex, with 18F-flutemetamol [6, 7], Pittsburg compound B [8, 9] and 18F-
florbetapir[10] being the most widely studied. These tracers have been validated against Aβ plaque load 
determined using histopathology[11-14], and a high degree of concordance has also been demonstrated 
between the tracers[12, 15]. 
For CSF measurements of Aβ1-42, several immunoassays are available and used in many clinical 
laboratories [16]. The concentration of Aβ1-42 in CSF is approximately 50% lower in AD patients than in 
cognitively normal elderly, reflecting the deposition of the peptide in senile plaques in the brain[17]. The 
combination of CSF Aβ1-42 with total tau (T-tau) and phosphorylated tau (P-tau) can predict progression 
from mild cognitive impairment (MCI) to AD as early as ten years before clinical dementia [18-21]. 
Further, emerging evidence suggest that a ratio of CSF Aβ1-42 to Aβ1-40 is superior to CSF Aβ1-42 alone 
when detecting cortical Aβ pathology [22-26]. 
 
There is a very high concordance between CSF Aβ and amyloid PET measurements [27], but both PET 
and CSF methodologies suffer from similar standardization issues, especially regarding uniform cut-off 
levels but also in reproducibility [27-30]. Efforts to standardize procedures and harmonize levels between 
assay formats have been initiated to address these issues and to harmonize results across laboratories 
together within The Alzheimer’s Association Quality Control program for CSF biomarkers which 
currently involves 84 laboratories globally [29] as well as the International Federation of Clinical 
Chemistry Working Group for CSF proteins (IFCC WG-CSF). The production of a certified reference 
material (CRM), with exact levels of Aβ1-42 determined using a mass spectrometry (MS)-based reference 
measurement procedure (RMP), will enable the introduction of global cut-off levels and a more general 
use of Aβ1-42 in CSF as a diagnostic tool. Two RMPs using antibody independent MS for quantification of 
CSF Aβ1-42 [31, 32] have recently been accepted and listed by the Joint Committee for Traceability in 
Laboratory medicine (JCTLM database identification number C11RMP9).  
 
In the present study we compared our RMP for Aβ1-42 [31] with 18F-flutemetanol PET imaging to study the 
concordance between the methods. Further, since the CSF sample preparation allows quantification of 
multiple Aβ species within a single MS analysis, we also measured Aβ1-38 and Aβ1-40 using the same 
antibody-independent MS technique to analyze whether the ratios of Aβ1-42/Aβ1-40 or Aβ1-42/Aβ1-38 in CSF 
improve the diagnostic accuracy of cortical amyloid accumulation as compared with Aβ1-42 alone. 
 
Materials and methods 
Study population 
The study was approved by the Regional Ethics Committee in Lund, Sweden, and the Swedish Medical 
Products Agency, Sweden. All the patients provided their written informed consent to participate in the 
study. 
The study population was derived from the prospective and longitudinal Swedish BioFINDER study, 
which consecutively enrolled patients at three memory outpatient clinics in Sweden (further information 
available at: www.biofinder.se). The present study included 100 non-demented patients with mild 
cognitive complaints, who all had undergone lumbar puncture and 18F-flutemetamol PET. The patients 
were referred for assessment of their cognitive complaints and were included between 2010 and 2014. 
They were thoroughly assessed for their cognitive complaints by physicians with special interest in 
dementia disorders. The inclusion criteria were: 1) cognitive symptoms; 2) not fulfilling the criteria for 
dementia; 3) a Mini-Mental State Examination (MMSE) score of 24–30 points; 4) age 60–80 years; and 5) 
fluent in Swedish. The exclusion criteria were: 1) cognitive impairment that without doubt could be 
explained by another condition (other than prodromal dementias); 2) severe somatic disease; and 3) 
refusing lumbar puncture or neuropsychological investigation. 
 
CSF sampling and analysis 
The procedure and analysis of the CSF followed the Alzheimer’s Association Flow Chart for CSF 
biomarkers [17]. Lumbar CSF samples were collected at the three centers and analyzed according to a 
standardized protocol [17, 33]. 
 
18F-flutemetamol PET 
The deposition of cerebral Aβ was visualized with the PET tracer 18F-flutemetamol (approved by the 
European Medical Agency and the Food and Drug Administration). PET/CT scanning of the brain was 
conducted using a Philips Gemini TF PET scanner. Sum images, obtained 90-110 min post injection, were 
analyzed using the software NeuroMarQ (GE Healthcare). A volume of interest (VOI) template was 
applied for the following 9 bilateral regions: prefrontal, parietal, lateral temporal, medial temporal, 
sensorimotor, occipital, anterior cingulate, posterior cingulate/precuneus and a global neocortical 
composite region [34]. The standardized uptake value ratio (SUVR) was defined as the uptake in a VOI 
normalized for the cerebellar cortex uptake. Recently, we have established that the composite SUVR of 
18F-flutemetamol data show a bimodal distribution and can be separated in two populations (normal vs 
abnormal) using a cutoff of 1.42 SUVR [33]. 
 
Mass spectrometry 
Calibration and sample preparation 
Native (unlabeled) and 15N uniformly labeled Aβ1-38, Aβ1-40, Aβ1-42 and 13C uniformly labeled Aβ1-42 
(rPeptide, Bogart, GA, USA) were dissolved in 20% acetonitrile (ACN) and 1% ammonium hydroxide 
(NH4OH) to a concentration of 50 µg/mL. Aliquots were stored in -80° C. Artificial CSF (aCSF) was 
prepared as described elsewhere [35]. 
Calibration samples for Aβ1-42 were prepared in human CSF as previously described [31]. For Aβ1-38 and 
Aβ1-40, aCSF was spiked to a final concentration of 150, 500, 1000, 2000, 3000 and 4000pg/mL native 
Aβ1-38 and 1500, 5000, 10000, 20000, 30000 and 40000 pg/mL native Aβ1-40 and a constant concentration 
of 15N-Aβ1-38 and 15N-Aβ1-40 at 1600 pg/mL as internal standard (IS). 
CSF samples (180 µL) were spiked with 20 µL IS to a final concentration of 1600 pg/mL 13C-Aβ1-42, 15N-
Aβ1-38 and 15N-Aβ1-40. 
 
Solid phase extraction 
Solid phase extraction (SPE) using a mixed-mode cation exchange SPE 96-well plate (Oasis MCX 
µElution, Waters) was conducted as previously described [31]. In brief, 200 µL of 5 M guanidine 
hydrochloride was added to 200 µL spiked CSF (180 µL CSF with 20 µL IS) and mixed on a vortex mixer 
at 1000 rpm for 20 min before adding 200 µL of 4% aqueous phosphoric acid (total volume 600 µL). The 
SPE wells were washed with 200 µL methanol and equilibrated with 200 µL 4% aqueous phosphoric acid 
prior to loading the prepared samples (600 µL). The wells were washed twice with 200 µL 4% phosphoric 
acid before the analytes were eluted with 2 × 50 µL 75% ACN and 2.5% NH4OH. The eluates were 
collected in 0.75 mL tubes (Micronic, Lelystad, The Netherlands) and dried using vacuum centrifugation. 
Prior to analysis the samples were re-dissolved in 50 µL aqueous 20% ACN and 1% NH4OH and gently 
mixed on shaker for 20 min at room temperature. The vials were briefly centrifuged to collect the volume 
at the bottom of the vial and placed in the autosampler. 
 
Chromatography 
Chromatography was performed using an UltiMate 3000 binary pump, column oven and autosampler 
(Thermo Scientific, Amsterdam, Netherlands). Separation was performed using a reversed-phase 
monolithic ProSwift RP-4H 1.0 mm x 250 mm column (Thermo Scientific, Sunnyvale, CA, USA) 
maintained at 50°C. Mobile phase A consisted of aqueous 5% ACN with 0.075% NH4OH and mobile 
phase B of aqueous 95% ACN with 0.025% NH4OH. Gradient elution was performed after injection of 25 
µL processed sample at a flow rate of 0.3 mL/min with the following linear gradient steps: 0 min, 5% B; 1 
min, 5% B; 6 min, 20% B; 7 min, 90% B; 9 min, 90% B; 10 min, 5% B; 15 min, 5% B.  Eluent flow 
before 2 min and after 10 min was discarded using a divert valve to reduce contamination of the mass 
spectrometer. The total run time per sample was 15 minutes (including column re-equilibration). CSF 
samples were injected between calibrators (six calibrators low to high), blank, response factor and QC 
samples. Blanks were injected after each calibrator set, each response factor sample and each set of 
unknowns. The autosampler injector needle and tubing were washed after each sample injection with a 
solution consisting of aqueous 50% ACN with 1% NH4OH.  
 
Mass spectrometric analysis 
Quantification was performed using a quadrupole-Orbitrap hybrid mass spectrometer (Q Exactive) 
equipped with a heated electrospray ionization source (HESI-II) (Thermo Scientific, Bremen, Germany). 
The following parameters were obtained by tuning the instrument on native Aβ1-38, Aβ1-40 and Aβ1-42 
infused directly: sheath gas 50, auxillary gas 6, spray voltage 4.40 kV, S-lens RF 61, heater +190 °C, and 
capillary temperature +350 °C. Parallel reaction monitoring [36] was performed by fragmenting the 4+ 
charge states precursor ions for native and labeled Aβ1-38, Aβ1-40 & Aβ1-42 and using the sum the fragment 
peak areas of the product ions post-acquisition (Supplemental Data Table 1). The precursors were isolated 
with an isolation width of 2.5 m/z followed by fragmentation using a normalized collision energy of 17.0 
(Targeted-MS2). Fragment spectra were recorded at a resolution of 17500 using an automatic gain control 
target of 2×105 charges and a maximum injection time of 250 ms. Spectra were internally mass calibrated 
using lock masses recorded in full scan mode during retention time 2.0 – 2.5 min. Before starting an 
analysis, a system suitability test was performed with an aqueous solution containing native Aβ1-42, 13C-
Aβ1-42 and 15N-Aβ1-42 (250 pg/mL each). Resulting signals were required to have a signal-to-noise ratio 
(S/N) ≥ 10. 
 
Data processing 
Xcalibur 2.2 Quanbrowser (Thermo Scientific, Waltham, MA, USA) was used for raw file processing 
(peak integration and S/N were determined using the built in ICIS peak detection algorithm and generation 
of calibration curve for the 15N-calibrators). Quantification was performed using summed transitions. 
Value assignment for endogenous Aβ of unknown samples was calculated in Excel using the calibration 
function constructed in Quan browser software. 
 
Validation of the mass spectrometry method 
Measurement range 
Linearity, measurement range, and limits of quantification were evaluated by measuring calibration 
samples (150-4000 pg/mL and 1500-40000 pg/mL for Aβ1-38 and Aβ1-40 respectively). The linear 
calibration curve had to have an R2 >0.99 (of the Pearson correlation coefficient). The coefficient of 
variation (CV) for the back calculated concentrations of the data from the calibrator curves had to be 
<20% at the lower level of quantification (LLOQ) and upper level of quantification (ULOQ), while <15% 
for all other levels. Calibration curve data from five runs were used and the relative error of the back-
calculated concentrations for the calibrators was plotted as a function of concentration. 
 
Precision 
Two human CSF pools with high and low concentrations, respectively, of Aβ1-42 were constructed and 
aliquoted in 25 vials each. The vials were stored at -80 °C pending analysis. Five replicates for each 
concentration were measured in five different days. The experiments were performed by two technicians 
on a single SPE batch of the assay. For the precision samples the repeatability (CVr) had to be < 10% and 
the intermediate precision (CVRW) < 15%. One-way ANOVA was used to calculate CVr and CVRW in 
accordance with ISO 5725-2 employing a published excel tool [37].  
 
Sample stability 
We investigated the effect on measured concentrations as a function of freeze-thaw cycles and different 
storage conditions. Five different fresh CSF samples were each divided into nine aliquots. One aliquot 
from each sample was immediately placed in the -80 °C freezer (aliquot 1) and the rest were treated as 
follows. Aliquot 2-5, two to five freeze/thaw (F/T) cycles, respectively (aliquot 1 undergoes one cycle). 
Aliquot 6, twenty-four hours (24h) at 5-8 °C; aliquot 7, one week (1w) at 5-8 °C; aliquot 8, twenty-four 
hours at room temperature (RT); and aliquot 9, one month (1M) at -20 °C. 
At the end of the incubations or freeze/thaw cycles the aliquots were placed at -80 °C pending analysis. 
All nine aliquot for a given sample were run in duplicates. Aliquot 1 serves as a reference sample to which 
the other were compared, calculating recoveries relative to the reference sample. The evaluation is 
qualitative and there are no quantitative demands for sample stability but useful information can be 
obtained on how to store the samples with minimal effect on the results. 
 
Statistical Analysis 
An unbiased cutoff value for an abnormal 18F-flutemetamol scan finding has previously been established 
[33] using mixture modeling [38]. Cutoff values were established for Aβ1-42 concentration, the Aβ1-42/Aβ1-
40 and the Aβ1-42/Aβ1-38 ratios using the same method. 
 
Results 
Validation of the mass spectrometry method 
Measurement range 
The relative errors for the back-calculated calibrators were below 15% in the whole range defined by the 
calibrator curve (150-4000 pg/mL and 1500-40000 pg/mL for Aβ1-38 and Aβ1-40 respectively, 
Supplemental Data Figure 1). The calibration curves for the different analytes all had a goodness-of-fit of 
R2 >0.99. 
 
Precision 
CVr and CVRW for both high and low levels were well below demanded limits for the different analytes 
(Supplemental Table 2). 
 
Sample stability 
A sample can go through up to five freeze/thaw cycles with no significant effect on the measured 
concentration of the analyte (Supplemental Figure 2). Storage in -80° C is preferred, but the other storage 
conditions tested were also acceptable. 
 
Association between CSF Aβ and 18F-flutemetamol PET 
The unbiased cutoff for CSF Aβ1-42 to distinguish two populations within the sample set was 1059 pg/mL. 
Comparing the 18F-flutemetamol PET and CSF Aβ1-42 concentrations using this cutoff showed 66% 
concordance (Figure 1A). We further studied the association between 18F-flutemetamol PET and the ratios 
of CSF Aβ1-42/Aβ1-40 and Aβ1-42/Aβ1-38. The unbiased cutoff values to distinguish two populations within 
the sample set were 0.085 for the CSF Aβ1-42/Aβ1-40 ratio and 0.40 for the CSF Aβ1-42/Aβ1-38 ratio. 
Comparing the 18F-flutemetamol PET and CSF Aβ ratios using these cutoff values showed 89% 
concordance for both Aβ1-42/Aβ1-40 (Figure 1B) and Aβ1-42/Aβ1-38 (Figure 1C).  
 
When dichotomized for positive or negative amyloid PET, using cutoff values derived from receiver 
operating characteristic  (ROC) analysis and Youden’s index, the CSF Aβ1-42 concentration could 
distinguish individuals with an abnormal amyloid PET scan finding with a sensitivity of 82% and a 
specificity of 81%, area under the ROC curve (AUC) 0.85 (95% CI, 0.78-0.93). For the CSF Aβ1-42/Aβ1-40 
ratio the sensitivity and specificity was 96% of 91% respectively with an AUC of 0.95 (95% CI, 0.90-
1.00), and for the CSF Aβ1-42/Aβ1-38 the sensitivity and specificity was 88% and 96% respectively with an 
AUC of 0.94 (95% CI, 0.88-0.99) (Figure 1D). 
 
Discussion 
In this study we demonstrate the accuracy of Aβ measurements in CSF using a MS-based RMP to 
determine cortical Aβ deposition. The CSF Aβ measurements were in good agreement with plaque load 
measured using 18F-flutemetamol PET where the level of CSF Aβ1-42 identified an abnormal amyloid PET 
scan with sensitivities and specificities of more than 80%, while using the CSF Aβ1-42/ Aβ1-40 ratio 
increased the sensitivities and specificities to more than 90%. 
 
The cutoff for pathological CSF Aβ1-42 using MS was 1059 pg/mL or less, which is significantly higher 
compared to the cutoff values for many immunoassays used in clinical routine. While this difference in 
concentration may be explained by differences in calibration and calibrator characterization, it may also 
reflect the fundamental difference in quantitation between MS and immunoassays: MS does not rely on 
antibodies and is therefore unaffected by matrix interferences such as epitope masking. The use of 
denaturing agents in the sample preparation for MS may make a protein-bound fraction of Aβ accessible 
to the analysis. This difference highlights the need for a CRM for CSF Aβ1-42. 
 
Both CSF and plasma contains a variety of Aβ peptides, where Aβ1-40 is around ten times more abundant 
than Aβ1-42 [39], and there is a variation between individuals regarding the amount of all (total) Aβ 
peptides produced [26]. Consequently, when using only Aβ1-42, low total Aβ producers might be false 
positive for AD while the opposite might be true for high producers. While the levels of Aβ1-40 in CSF are 
unchanged in AD, the ratio of Aβ1-42/Aβ1-40 has been shown to improve the diagnostic accuracy of AD 
[22-26, 40]. For this study we expanded the previously published MS method to quantify Aβ1-42 in human 
CSF [31] to also include Aβ1-40 and Aβ1-38 with results from the validation showing good precision and 
sample stability for the analytes (see Supplemental data). The present results are in agreement with a 
recent study, which showed that the CSF Aβ1-42/Aβ1-40 ratio is better than CSF Aβ1-42 to reliably determine 
abnormal cortical Aβ deposition, even when using different types of immunoassays [22]. These results 
strongly suggest that the Aβ1-42/Aβ1-40 ratio can accurately detect cortical amyloid pathology and can be 
used to improve the diagnostic work-up of AD in the clinic and when recruiting early AD patients to 
clinical trials evaluating new disease-modifying therapies.  
Since cognitively normal individuals can exhibit cortical Aβ accumulation, and patients showing cognitive 
symptoms might be clinically misdiagnosed for AD without Aβ pathology, an important aspect of this 
study was to use an objective method such as amyloid PET as a “standard of truth” instead of clinical 
diagnosis to only include true AD cases. 
 
In conclusion, the presented results show that the Aβ1-42/Aβ1-40 ratio measured in CSF is strongly 
associated with the amount of cortical Aβ deposition assessed by PET. Further, the data suggest that a 
ratio of Aβ1-42/Aβ1-40 (or Aβ1-42/Aβ1-38) is superior to Aβ1-42 alone. 
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Figure captions 
Figure 1. 
Scatterplot showing (A) CSF Aβ1-42 concentrations with an unbiased cutoff determined to 1059 pg/mL 
(horizontal dashed line), (B) the CSF Aβ1-42/Aβ1-40 ratios with a cutoff determined at 0.0852 (horizontal 
dashed line) and (C) the CSF Aβ1-42/Aβ1-38 ratios with a cutoff determined at 0.402 and the SUVR values 
of 18F-flutemetanol and SUVR at 1.42 (vertical dashed line). The blue quadrants indicate abnormal 
amyloid PET and CSF Aβ while tan quadrants indicate normal amyloid PET and CSF Aβ. White 
quadrants indicate discordant results.  
(D) The area under the receiver operating characteristic (ROC) curve (AUC) for the accuracy of CSF Aβ1-
42 (blue line, AUC 0.85), CSF Aβ1-42/Aβ1-40 ratios (red line, AUC 0.95) and CSF Aβ1-42/Aβ1-38 ratios (green 
line, AUC 0.94) to predict an abnormal 18F-flutemetanol scan (standardized uptake value ratio [SUVR] 
> 1.42). 
 
Figures 
Figure 1 
 
Supplemental Data 
Supplemental Table 1. Retention times, precursor and product ions mass-to-charge ratios for Aβ peptides. 
Peptide RT 
(min) 
Precursor 
(m/z) 
Products (m/z) 
Aβ1-38 5.98 1033.90 915.00; 943.29; 976.09; 1000.87; 1015.13; 1125.21; 1162.93; 
1200.64; 1219.66; 1257.38; 1301.11 
15N-Aβ1-38 5.98 1046.57 926.42; 954.96; 988.01; 1013.04; 1027.55; 1139.44; 1177.50; 
1215.55; 1234.89; 1272.94; 1317.01 
Aβ1-40 6.5 1083.47 915.00; 943.29; 953.69; 976.09; 1000.87; 1015.13; 1029.40; 
1054.18; 1125.21; 1162.93; 1200.64; 1219.66; 1257.38; 
1301.11; 1334.16; 1353.17; 1372.19 
15N-Aβ1-40 6.5 1096.63 926.42; 954.96; 965.28; 988.01; 1013.04; 1027.55; 1042.06; 
1067.09; 1139.44; 1177.50; 1215.55; 1234.89; 1272.94; 
1317.01; 1350.38; 1369.73; 1389.08 
Aβ1-42 6.9 1129.58 915.19; 943.21; 975.98; 1000.74; 1029.51; 1054.03; 1078.79; 
1107.06; 1163.23; 1200.25; 1257.29; 1300.96; 1333.66; 
1372.00; 1405.02 
15N-Aβ1-42 6.9 1143.00 926.41; 954.68; 987.95; 1012.71; 1041.22; 1066.99; 1091.75; 
1120.28; 1177.18; 1215.55; 1272.58; 1316.92; 1349.94; 
1388.63; 1422.31 
13C-Aβ1-42 6.9 1179.50 955.33; 985.11; 1019.37; 1045.14; 1074.65; 1100.67; 1126.69; 
1156.40; 1253.43; 1313.14; 1358.50; 1393.19; 1432.21; 1466.90
 
Abbreviations: RT, Retention time (minutes). m/z, mass-to-charge ratio.
 Supplemental Table 2. Precision, Aβ1-38. n=5 per level and day over 5 days. 
Sample 
Average 
concentration 
(pg/mL) 
sr (pg/mL) CVr     (%) sRW (pg/mL) CVRw (%) 
HIGH 2937.9 136.5 4.6 202.6 6.9 
LOW 2071.9 71.9 3.5 145.7 7.0 
 
Abbreviations: CV, coefficient of variation. s, standard deviation. r, repeatability. Rw, intermediate 
precision. 
 
Supplemental Table 3. Precision, Aβ1-40. n=5 per level and day over 5 days. 
Sample 
Average 
concentration 
(pg/mL) 
sr (pg/mL) CVr (%) sRW (pg/mL) CVRw (%) 
HIGH 4197.4 171.8 4.1 252.5 6.0 
LOW 2737.5 93.5 3.4 166.5 6.1 
 
Abbreviations: CV, coefficient of variation. s, standard deviation. r, repeatability. Rw, intermediate 
precision. 
 
Supplemental Table 4. Precision, Aβ1-42. n=5 per level and day over 5 days. 
Sample 
Average 
concentration 
(pg/mL) 
sr (pg/mL) CVr (%) sRW (pg/mL) CVRw (%) 
HIGH 1066 61.5 5.8 111.5 10.5 
LOW 301 21.6 7.1 32.3 10.7 
 
 
Supplemental Table 5. Precision, Aβ1-42/Aβ1-40. n=5 per level and day over 5 days. 
Sample Average ratio sr CVr (%) sRW CVRw (%) 
HIGH 0.254 0.011 4.4 0.017 6.6 
LOW 0.110 0.006 5.5 0.011 10.2 
 
Abbreviations: CV, coefficient of variation. s, standard deviation. r, repeatability. Rw, intermediate 
precision. 
 
Supplemental Table 5. Precision, Aβ1-42/Aβ1-38. n=5 per level and day over 5 days. 
Sample Average ratio sr CVr (%) sRW CVRw (%) 
HIGH 0.363 0.019 5.2 0.026 7.1 
LOW 0.146 0.009 6.2 0.014 9.9 
 
Abbreviations: CV, coefficient of variation. s, standard deviation. r, repeatability. Rw, intermediate 
precision. 
 
Supplemental Figure 1. Measurement range for (A) Aβ1-38, (B) Aβ1-40 and (C) Aβ1-42. 
 Supplemental Figure 2. Sample stability for (A-B) Aβ1-38, (C-D) Aβ1-40, (E-F) Aβ1-42, (G-H) Aβ1-42/Aβ1-40 
ratio and (I-J) Aβ1-42/Aβ1-38 ratio. 
 
